CagriSema

Two appetite drugs in one combination. Cagrilintide is an amylin analogue; semaglutide acts on GLP-1. People discuss the pair for earlier meal-stop fullness and fewer urges to snack. It is systemic, rather than a local recovery peptide. Novo Nordisk — REDEFINE 1 safety and post hoc context (Official context · Accessed 2026-09-30) · Cagrisema blend and sema (Community discussion · Accessed 2026-09-30)

Trial injections and research blends differ. The trial uses injection beneath the skin. Forums discuss separate components and premixed vials sold under the same name; that name does not verify contents, ratio, sterility or equivalence to the trial pen. Davies et al. — Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (Official context · Accessed 2026-09-30) · Help. (Community discussion · Accessed 2026-09-30)

Source context — Novo Nordisk — REDEFINE 1 safety and post hoc context: Manufacturer release, not an independent analysis; only core identity and GI context used. Historical approval statement not treated as current.

Source context — Cagrisema blend and sema: Research-subject euphemisms, unverified blends, extra semaglutide and some tirzepatide use. Amounts may mean total or per component; no preparation or vendor instructions retained.

Source context — Davies et al. — Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes: Sponsor-funded adults with T2D; trial conditions and device differ from informal products. No supplement or individual dosing recommendation.

Source context — Help.: Delivered dose, product contents, route accuracy and cause unresolved. Replies make conflicting arithmetic/overdose assumptions; no recipe or correction advice carried over.

CagriSema combines cagrilintide and semaglutide, two injectable appetite drugs. Community discussion centers on quieter food thoughts, earlier fullness and renewed weight loss, alongside fatigue, stomach problems and uneven responses. Trial CagriSema and informal research blends are different products.

Fullness is different from quiet cravings. A bodybuilding-forum user hoped for less initial hunger but instead became full after a few bites. A trial participant still fought food thoughts while eating smaller portions. Feeling full sooner does not necessarily mean less hunger before a meal or fewer recurring food thoughts. What are your experiences with Cagrilintide? — page 2 (Community discussion · Accessed 2026-09-30) · Calling All Cagrisema Brothers & Sisters (Personal report · Accessed 2026-09-30)

OP five-month plateau at reported 2.4 stage; PalpitationUnable280 intolerance above 0.5; DoctorClaraOswald persistent hunger reduction with plateau. Opened lines 19–91. Quitting CagriSema Trial (Personal report · Accessed 2026-09-30)

Fatigue can outweigh the appetite benefit. Opened sema-combination accounts describe needing naps or feeling too exhausted to function. Older reports add brain fog and a day-after low mood. These experiences deserve attention even when appetite or weight improves. What does Cag feel like? (Community discussion · Accessed 2026-09-30) · Tired (Personal report · Accessed 2026-09-30)

Source context — What are your experiences with Cagrilintide? — page 2: Component-adjacent bodybuilding thread with multiple stacks and commercial surroundings. Used only for appetite/fullness distinction and repeated PK lore; not direct CagriSema efficacy.

Source context — Calling All Cagrisema Brothers & Sisters: Mixture of open-label and blinded self-described participants. Single-number stage descriptions do not independently confirm each component amount.

Source context — Quitting CagriSema Trial: Self-identified trial participation; OP infers active allocation from side effects, which is not confirmation. Proposals to reset sensors or add high-dose semaglutide are speculation.

Source context — What does Cag feel like?: Mixed sema, tirz and reta contexts; the specific semaglutide combination reports are identified separately. Amount units/timing only retained where given. No measured mechanism or safety.

Source context — Tired: Unverified product and amount; weight loss does not establish causality. Supplement replies are not evidence of a remedy.

Paired trial report: 0.25 mg of each, weekly. A blinded first-week participant described that possible assigned injection, or semaglutide alone or placebo. Other trial posters name 0.5, 1.0, 1.7 and 2.4 stages without consistently specifying both components. CagriSema* 1st Week (Personal report · Accessed 2026-09-30) · What are your symptoms on higher dose? (Personal report · Accessed 2026-09-30) · Calling All Cagrisema Brothers & Sisters (Personal report · Accessed 2026-09-30)

Separate-component talk: cagri 0.125–0.5 mg alongside sema. One sema-stack report used 0.125 mg cagri per injection three times; another describes weekly 0.125 then 0.25 with sema listed as 2.5. Older discussion describes holding cagri at 0.25–0.5 while sema stays at a familiar amount. These are different reports, not a ladder. What does Cag feel like? (Community discussion · Accessed 2026-09-30)

Blend totals and per-component mg are easily confused. One reply calls a 1:1 blend addition 0.25 of each component; another reports 0.125 CagriSema four days after 1.7 mg sema without clarifying the split. A separate 2.5 mg weekly blend report also leaves the component meaning ambiguous. Cagrisema blend and sema (Community discussion · Accessed 2026-09-30) · Help. (Community discussion · Accessed 2026-09-30)

Source context — CagriSema* 1st Week: Blinded participant: CagriSema, semaglutide or placebo possible. Route injection; cannot identify active allocation from symptoms. Deleted OP account; self-report.

Source context — What are your symptoms on higher dose?: Mixed trial and informal products, some additional retatrutide. Single dose numbers may be stage shorthand; do not silently convert to verified paired doses.

Source context — Calling All Cagrisema Brothers & Sisters: Mixture of open-label and blinded self-described participants. Single-number stage descriptions do not independently confirm each component amount.

Source context — What does Cag feel like?: Mixed sema, tirz and reta contexts; the specific semaglutide combination reports are identified separately. Amount units/timing only retained where given. No measured mechanism or safety.

Source context — Cagrisema blend and sema: Research-subject euphemisms, unverified blends, extra semaglutide and some tirzepatide use. Amounts may mean total or per component; no preparation or vendor instructions retained.

Source context — Help.: Delivered dose, product contents, route accuracy and cause unresolved. Replies make conflicting arithmetic/overdose assumptions; no recipe or correction advice carried over.

About 6 hours in one blinded first-dose account. The reporter noticed fullness and reduced appetite, then burps, hiccups and reflux. The received drug was unknown. A reply felt normal and hungry after the first injection; immediate response cannot identify a trial arm. CagriSema* 1st Week (Personal report · Accessed 2026-09-30)

One blend-addition report: 2–3 days of satiety. The report involved sema 1.7 mg with an ambiguously labeled 0.125 blend addition four days later, plus a few hours of fatigue. It is not a dependable weekly duration for the trial combination. Cagrisema blend and sema (Community discussion · Accessed 2026-09-30)

Adverse effects: roughly 1–2 days in some accounts. A sema-stack user felt flu-like exhaustion for two days after each 0.125 mg cagri exposure. A trial-like account describes Friday-night injections followed by Saturday/Sunday nausea. Appetite benefit and unwanted effects need separate clocks. What does Cag feel like? (Community discussion · Accessed 2026-09-30) · What are your symptoms on higher dose? (Personal report · Accessed 2026-09-30)

Measured human kinetics are component-specific. Enebo’s weekly SC study measured cagri half-life at 159–195 hours and sema at 145–165 hours; blood peaks were 24–72 and 12–24 hours respectively. These are not felt-onset values. Earlier cagri cohorts spanned 0.16–4.5 mg with sema toward 2.4 mg. Enebo et al. — phase 1b concomitant cagrilintide and semaglutide (Official context · Accessed 2026-09-30)

Source context — CagriSema* 1st Week: Blinded participant: CagriSema, semaglutide or placebo possible. Route injection; cannot identify active allocation from symptoms. Deleted OP account; self-report.

Source context — Cagrisema blend and sema: Research-subject euphemisms, unverified blends, extra semaglutide and some tirzepatide use. Amounts may mean total or per component; no preparation or vendor instructions retained.

Source context — What does Cag feel like?: Mixed sema, tirz and reta contexts; the specific semaglutide combination reports are identified separately. Amount units/timing only retained where given. No measured mechanism or safety.

Source context — What are your symptoms on higher dose?: Mixed trial and informal products, some additional retatrutide. Single dose numbers may be stage shorthand; do not silently convert to verified paired doses.

Source context — Enebo et al. — phase 1b concomitant cagrilintide and semaglutide: Primary sponsor-funded human paper hosted on third-party mirror. Small selected population; not gray-product validation or felt-effect timing. Supplementary appendix not inspected.

Reports describe months of weekly use. Participant logs describe months at a lower stage and roughly a year on study. The older community record also contains 8–12-week tests and 12–24-week planning windows; these are plans, not validated on/off cycles. Calling All Cagrisema Brothers & Sisters (Personal report · Accessed 2026-09-30)

Restart amounts reported: 0.25/0.25 or 0.5/0.5 mg. The older record describes those lower paired restarts after gaps and renewed GI trouble on returning to a former maximum. An opened thread reports a month off after illness at 1.0, then restarting low. None establishes a universal restart rule. What are your symptoms on higher dose? (Personal report · Accessed 2026-09-30)

Holding a lower stage is part of the discussion. One trial poster stayed at 1.7 for months because of nausea; another reports fatigue without nausea there. The older record includes longer-than-four-week holds at 1.0/1.0 or 1.7/1.7. A low number does not guarantee tolerability. Calling All Cagrisema Brothers & Sisters (Personal report · Accessed 2026-09-30) · What are your symptoms on higher dose? (Personal report · Accessed 2026-09-30)

After stopping, the timeline varies. One former participant felt effects for about a month, then regained 15 lb over two months. Another stayed weight-stable four months before regaining 15 lb over five months. Taper preferences and fear of regain are discussion, not a proven stopping method. Study ending- trying to plan (Personal report · Accessed 2026-09-30)

Source context — Calling All Cagrisema Brothers & Sisters: Mixture of open-label and blinded self-described participants. Single-number stage descriptions do not independently confirm each component amount.

Source context — What are your symptoms on higher dose?: Mixed trial and informal products, some additional retatrutide. Single dose numbers may be stage shorthand; do not silently convert to verified paired doses.

Source context — Study ending- trying to plan: Different self-described studies, unknown allocations, post-study habits and other medicines. Weight maintenance is not proof of continued drug exposure.

Cagri plus tirz or reta is a different stack. Those logs help explain cagrilintide talk but are not CagriSema. Extra semaglutide alongside a CagriSema blend also changes the overall pairing. Cagrisema blend and sema (Community discussion · Accessed 2026-09-30)

More stacking makes attribution harder. Cagri-plus-tirz/reta reports and older AOD-9604, cardarine or stimulant combinations concern different mixtures. Tingling, injection-site irritation and nausea also appear in the record; none can be assigned to one ingredient from a stack log. What are your symptoms on higher dose? (Personal report · Accessed 2026-09-30)

Source context — Cagrisema blend and sema: Research-subject euphemisms, unverified blends, extra semaglutide and some tirzepatide use. Amounts may mean total or per component; no preparation or vendor instructions retained.

Source context — What are your symptoms on higher dose?: Mixed trial and informal products, some additional retatrutide. Single dose numbers may be stage shorthand; do not silently convert to verified paired doses.

Fatigue can outweigh the appetite benefit. Opened sema-combination accounts describe needing naps or feeling too exhausted to function. Older reports add brain fog and a day-after low mood. These experiences deserve attention even when appetite or weight improves. What does Cag feel like? (Community discussion · Accessed 2026-09-30) · Tired (Personal report · Accessed 2026-09-30)

Persistent vomiting or severe abdominal pain needs assessment. A blend poster described repeated vomiting through the next morning; the delivered amount remains unresolved. Semaglutide labeling separately warns about pancreatitis, gallbladder problems and dehydration-related kidney injury. Help. (Community discussion · Accessed 2026-09-30) · Wegovy prescribing information — semaglutide component cautions (Official context · Accessed 2026-09-30)

Strong fullness can crowd out nutrition. One participant tracks intake because appetite is absent. Protein and lifting appear in older community discussion, but neither the pair nor those habits establish guaranteed muscle preservation. What are your symptoms on higher dose? (Personal report · Accessed 2026-09-30)

Semaglutide risks still matter in the combination. Its label flags a history of medullary thyroid cancer, MEN2 (an inherited endocrine condition), pregnancy, severe slow stomach emptying, and low blood sugar with insulin or medicines that increase insulin release. These are component cautions, not approved combination labeling. Wegovy prescribing information — semaglutide component cautions (Official context · Accessed 2026-09-30)

Source context — What does Cag feel like?: Mixed sema, tirz and reta contexts; the specific semaglutide combination reports are identified separately. Amount units/timing only retained where given. No measured mechanism or safety.

Source context — Tired: Unverified product and amount; weight loss does not establish causality. Supplement replies are not evidence of a remedy.

Source context — Help.: Delivered dose, product contents, route accuracy and cause unresolved. Replies make conflicting arithmetic/overdose assumptions; no recipe or correction advice carried over.

Source context — Wegovy prescribing information — semaglutide component cautions: Wegovy is semaglutide, not a CagriSema label. Risk rates and specific patient instructions cannot be transferred wholesale to experimental combinations. Version date not independently recorded.

Source context — What are your symptoms on higher dose?: Mixed trial and informal products, some additional retatrutide. Single dose numbers may be stage shorthand; do not silently convert to verified paired doses.